Janssen: Positive Topline Results for JNJ-2113 for Plaque Psoriasis

 

• A greater proportion of patients achieved 100 percent improvement in skin clearance at the highest dose level tested compared to placebo, at week 16
• Phase 3 clinical development in moderate-to-severe plaque psoriasis is planned

 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis (PsO).¹ The trial achieved all primary and secondary efficacy endpoints. A greater proportion of patients who received JNJ-2113 achieved PASI 75 (primary endpoint) as well as PASI 90 and PASI 100 (75, 90 and 100 percent improvement in skin lesions as measured by the Psoriasis Area and Severity Index, respectively)^a compared to placebo, at week 16.¹ Trial results for JNJ-2113 demonstrated a profile¹ that supports its advancement into Phase 3 clinical development for moderate-to-severe plaque PsO in adult patients.

https://www.biospace.com/article/releases/janssen-announces-positive-topline-results-for-jnj-2113-a-novel-first-and-only-oral-il-23-receptor-antagonist-peptide-in-development-for-moderate-to-severe-plaque-psoriasis/